TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Hydrotherapy in Pain and Quality of Sleep's Cycles in Preterm Newborn on Neonatal Intensive Care Units
Brief Summary: Researchers suggest that the protection of the cycles of sleep is essential for neurodevelopment, learning, memory and preservation of brain plasticity to the individual's life. Recent research shows that technical bath promote reduction of crying, anxiety and improves the behavior of newborns.


Options:
A: Arm Label: Before Hidrotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hidrotherapy; Type: EXPERIMENTAL; Interventions: Other: Aquatic Physical Therapy | Intervention Type: OTHER; Name: Aquatic Physical Therapy; Assigned to Arm(s): Hidrotherapy
B: Arm Label: Pentacel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentacel (DPTaP+Hib) | Arm Label: Prevnar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prevnar (conjugated pneumococcal vaccine) | Intervention Type: DRUG; Name: Pentacel (DPTaP+Hib); Assigned to Arm(s): Pentacel | Intervention Type: DRUG; Name: Prevnar (conjugated pneumococcal vaccine); Assigned to Arm(s): Prevnar
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: pillow | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pillow; Assigned to Arm(s): 1
D: Arm Label: A; Type: OTHER; Interventions: Other: aromatherapy massage | Arm Label: B; Type: OTHER; Interventions: Other: aromatherapy massage | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: aromatherapy massage; Assigned to Arm(s): A, B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Hydrotherapy in Pain and Quality of Sleep's Cycles in Preterm Newborn on Neonatal Intensive Care Units
Brief Summary: Researchers suggest that the protection of the cycles of sleep is essential for neurodevelopment, learning, memory and preservation of brain plasticity to the individual's life. Recent research shows that technical bath promote reduction of crying, anxiety and improves the behavior of newborns.


Options:
A: Intervention Type: PROCEDURE; Name: Percutaneous Suprapubic Aspiration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Urethral Catheterization; Assigned to Arm(s): N/A
B: Arm Label: Before Hidrotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hidrotherapy; Type: EXPERIMENTAL; Interventions: Other: Aquatic Physical Therapy | Intervention Type: OTHER; Name: Aquatic Physical Therapy; Assigned to Arm(s): Hidrotherapy
C: Arm Label: OH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Arm Label: LH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Intervention Type: PROCEDURE; Name: Hernia repair; Assigned to Arm(s): LH, OH
D: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Educational Video - Sham, Drug: Sucrose Placebo (water), Drug: Lidocaine Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose Placebo (water), Drug: Lidocaine Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose, Drug: Lidocaine Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose, Drug: Lidocaine | Intervention Type: BEHAVIORAL; Name: Educational video - Active; Assigned to Arm(s): Group 2, Group 3, Group 4 | Intervention Type: BEHAVIORAL; Name: Educational Video - Sham; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Sucrose Placebo (water); Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: Lidocaine Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3 | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Group 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Comparison of Warm Water Infusion in Lieu of Air Insufflation vs. Air Insufflation for Aiding Colonoscopy Insertion in Sedated Patients Undergoing Colorectal Cancer (CRC) Screening and Surveillance.
Brief Summary: Compared with the conventional (air) method, patients examined by the study (water) method have lower pain scores and require less medication but have similar cecal intubation rate and willingness to repeat future colonoscopy.


Options:
A: Arm Label: Air colonoscopy; Type: N/A; Interventions: N/A | Arm Label: Water colonoscopy; Type: N/A; Interventions: N/A
B: Arm Label: CO2; Type: EXPERIMENTAL; Interventions: Procedure: CO2 | Arm Label: Warm Water irrigation; Type: EXPERIMENTAL; Interventions: Procedure: Warm water | Intervention Type: PROCEDURE; Name: CO2; Assigned to Arm(s): CO2 | Intervention Type: PROCEDURE; Name: Warm water; Assigned to Arm(s): Warm Water irrigation
C: Intervention Type: PROCEDURE; Name: water infusion colonoscopy; Assigned to Arm(s): N/A
D: Arm Label: warm water; Type: EXPERIMENTAL; Interventions: Procedure: warm water irrigation | Arm Label: air; Type: ACTIVE_COMPARATOR; Interventions: Procedure: air insufflation | Intervention Type: PROCEDURE; Name: warm water irrigation; Assigned to Arm(s): warm water | Intervention Type: PROCEDURE; Name: air insufflation; Assigned to Arm(s): air

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Randomized Controlled Study of Rosuvastatin for Prevention of Contrast Induced Acute Kidney Injury in Patients With Diabetes and Slight to Moderate Renal Insufficient
Brief Summary: The number of cardiac angiography and percutaneous coronary interventions (PCI) has increased steadily in recent years. This has resulted in the increasing incidence of contrast-induced acute kidney injury (CIAKI). Major risk factors for CIAKI include older age, diabetes mellitus (DM), chronic kidney disease(CKD), the concurrent use of nephrotoxic drugs, hemodynamic instability, etc. Importantly, DM appears to act as a risk multiplier, meaning that in a patient with CKD it amplifies the risk of CIAKI.

The aim of this multicenter prospective, randomized, controlled study is to evaluate whether statins treatment during the perioperative period would reduce the risk of CIAKI in a high-risk population of patients with both type 2 diabetes mellitus (T2DM) and CKD undergoing coronary angiography or noncoronary angiography, and evaluate the influence of such potential benefit on short-term outcome.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rosuvastatin | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: rosuvastatin | Intervention Type: DRUG; Name: rosuvastatin; Assigned to Arm(s): 1, control
B: Arm Label: On Pump Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Coronary Artery Bypass Graft with the use of CPB | Arm Label: Off Pump Arm; Type: EXPERIMENTAL; Interventions: Procedure: Coronary Artery Bypass Graft without the use of CPB | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass Graft with the use of CPB; Assigned to Arm(s): On Pump Arm | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass Graft without the use of CPB; Assigned to Arm(s): Off Pump Arm
C: Arm Label: statin; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): statin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: High dose Atorvastatin 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Control, High dose Atorvastatin 80 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Varenicline Adherence and Outcomes in Homeless Smokers
Brief Summary: the purpose of the study is to see if varenicline in combination with motivational counseling helps homeless cigarette smokers quit smoking.


Options:
A: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Tailored/No Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended Tailored Counseling + NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Intervention Type: DRUG; Name: Nicotine polacrilex, Bupropion; Assigned to Arm(s): Brief Treatment, Extended NRT, Extended Tailored Counseling + NRT, Tailored/No Extended NRT
B: Arm Label: Group I (standard care); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Behavioral: Smoking Cessation Intervention | Arm Label: Group II (enhanced care); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Behavioral: Smoking Cessation Intervention, Other: Tobacco Cessation Counseling | Arm Label: Group III (intensive care); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Behavioral: Smoking Cessation Intervention, Behavioral: Telephone-Based Intervention, Other: Tobacco Cessation Counseling | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Group I (standard care), Group II (enhanced care), Group III (intensive care) | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Intervention; Assigned to Arm(s): Group I (standard care), Group II (enhanced care), Group III (intensive care) | Intervention Type: BEHAVIORAL; Name: Telephone-Based Intervention; Assigned to Arm(s): Group III (intensive care) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group II (enhanced care), Group III (intensive care)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Varenicline plus Motivational Interviewing counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Varenicline without counseling | Intervention Type: OTHER; Name: Varenicline plus Motivational Interviewing counseling; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Varenicline without counseling; Assigned to Arm(s): 2
D: Arm Label: All Nations Breath of Life (ANBL); Type: EXPERIMENTAL; Interventions: Behavioral: All Nations Breath of Life (ANBL), Drug: Pharmacotherapy | Arm Label: Nontailored (NT); Type: EXPERIMENTAL; Interventions: Behavioral: Nontailored program (NT), Drug: Pharmacotherapy | Intervention Type: BEHAVIORAL; Name: All Nations Breath of Life (ANBL); Assigned to Arm(s): All Nations Breath of Life (ANBL) | Intervention Type: BEHAVIORAL; Name: Nontailored program (NT); Assigned to Arm(s): Nontailored (NT) | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): All Nations Breath of Life (ANBL), Nontailored (NT)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Varenicline Adherence and Outcomes in Homeless Smokers
Brief Summary: the purpose of the study is to see if varenicline in combination with motivational counseling helps homeless cigarette smokers quit smoking.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Varenicline plus Motivational Interviewing counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Varenicline without counseling | Intervention Type: OTHER; Name: Varenicline plus Motivational Interviewing counseling; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Varenicline without counseling; Assigned to Arm(s): 2
B: Arm Label: Control (N=25); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch, Behavioral: In-person smoking cessation counseling | Arm Label: Financial rewards (N=25); Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine patch, Behavioral: In-person smoking cessation counseling, Behavioral: Contingent financial rewards for smoking abstinence | Arm Label: Text messaging (N=25); Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine patch, Behavioral: In-person smoking cessation counseling, Behavioral: Text messages to support smoking abstinence | Intervention Type: DRUG; Name: Transdermal nicotine patch; Assigned to Arm(s): Control (N=25), Financial rewards (N=25), Text messaging (N=25) | Intervention Type: BEHAVIORAL; Name: In-person smoking cessation counseling; Assigned to Arm(s): Control (N=25), Financial rewards (N=25), Text messaging (N=25) | Intervention Type: BEHAVIORAL; Name: Contingent financial rewards for smoking abstinence; Assigned to Arm(s): Financial rewards (N=25) | Intervention Type: BEHAVIORAL; Name: Text messages to support smoking abstinence; Assigned to Arm(s): Text messaging (N=25)
C: Arm Label: Integrated Intensive Smoking + Alcohol; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch plus nicotine gum/lozenge, Behavioral: Intensive Alcohol Intervention | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine patch plus nicotine gum/lozenge | Intervention Type: DRUG; Name: nicotine patch plus nicotine gum/lozenge; Assigned to Arm(s): Integrated Intensive Smoking + Alcohol, Usual Care | Intervention Type: BEHAVIORAL; Name: Intensive Alcohol Intervention; Assigned to Arm(s): Integrated Intensive Smoking + Alcohol
D: Arm Label: Active Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Nicotine replacement therapy, Behavioral: Contingency Management | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Active Contingency Management | Intervention Type: DRUG; Name: Nicotine replacement therapy; Assigned to Arm(s): Active Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Active Contingency Management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Varenicline Adherence and Outcomes in Homeless Smokers
Brief Summary: the purpose of the study is to see if varenicline in combination with motivational counseling helps homeless cigarette smokers quit smoking.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Telephone Care Coordination | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Other: Telephone Care Coordination with state Quitline | Intervention Type: OTHER; Name: Telephone Care Coordination; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Telephone Care Coordination with state Quitline; Assigned to Arm(s): Arm 2
B: Arm Label: Integrated Cessation Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tobacco Treatment | Intervention Type: BEHAVIORAL; Name: Tobacco Treatment; Assigned to Arm(s): Integrated Cessation Counseling, Usual Care
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Varenicline plus Motivational Interviewing counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Varenicline without counseling | Intervention Type: OTHER; Name: Varenicline plus Motivational Interviewing counseling; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Varenicline without counseling; Assigned to Arm(s): 2
D: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing Intervention for ETS Reduction | Arm Label: Education Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Program for ETS Reduction | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing Intervention for ETS Reduction; Assigned to Arm(s): Behavioral | Intervention Type: BEHAVIORAL; Name: Educational Program for ETS Reduction; Assigned to Arm(s): Education Only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Varenicline Adherence and Outcomes in Homeless Smokers
Brief Summary: the purpose of the study is to see if varenicline in combination with motivational counseling helps homeless cigarette smokers quit smoking.


Options:
A: Arm Label: High intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: High intensity disease management, Drug: Bupropion | Arm Label: Low intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Low intensity disease management, Drug: Bupropion | Arm Label: Comparison group; Type: OTHER; Interventions: Behavioral: Comparison group, Drug: Bupropion | Intervention Type: BEHAVIORAL; Name: High intensity disease management; Assigned to Arm(s): High intensity disease management | Intervention Type: BEHAVIORAL; Name: Low intensity disease management; Assigned to Arm(s): Low intensity disease management | Intervention Type: BEHAVIORAL; Name: Comparison group; Assigned to Arm(s): Comparison group | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Comparison group, High intensity disease management, Low intensity disease management
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Varenicline plus Motivational Interviewing counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Varenicline without counseling | Intervention Type: OTHER; Name: Varenicline plus Motivational Interviewing counseling; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Varenicline without counseling; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin), Multicenter Study, To Evaluate The Safety And Efficacy In 2 Doses Of Apixaban In Comparison To Warfarin, Administered For 12 Weeks In Subjects With NVAF
Brief Summary: To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.


Options:
A: Arm Label: Apixaban 5mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Apixaban 2.5mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin sodium | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban 5mg BID | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban 2.5mg BID | Intervention Type: DRUG; Name: Warfarin sodium; Assigned to Arm(s): Warfarin
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Warfarin placebo | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Warfarin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
C: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study In Order To Investigate Safety And Efficacy Of CP- 690 550 In Subjects With Moderate To Severe Ulcerative Colitis.
Brief Summary: The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.


Options:
A: Arm Label: CP-690,550 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP-690,550 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 10 mg BID
B: Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 0.5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 10 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 3 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 0.5 mg BID | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
D: Arm Label: CP-690,550 5 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,500 5 mg | Arm Label: CP-690,550 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 10 mg | Intervention Type: DRUG; Name: CP-690,500 5 mg; Assigned to Arm(s): CP-690,550 5 mg | Intervention Type: DRUG; Name: CP-690,550 10 mg; Assigned to Arm(s): CP-690,550 10 mg

Answer: B